Financial Data and Key Metrics Changes - Total as-reported revenue grew 9% in the third quarter, with constant currency organic revenue growth of 8% driven by volume and a 200 basis points price increase [4] - Gross margin declined 70 basis points to 43.9%, primarily due to increased tariffs and inflation [4] - EBIT margin decreased 40 basis points to 22.9% of revenue, mainly driven by the decline in gross margin [4] - Adjusted net income from continuing operations was $249.4 million, with earnings per diluted share increasing by 9% to $2.53 [5] - Free cash flow for the first nine months was $736.6 million, showing year-over-year improvement [6] Business Line Data and Key Metrics Changes - Healthcare segment saw constant currency organic revenue growth of 8%, with service growth at 11% and consumables at 8% [7] - Healthcare capital equipment revenue increased by 7%, with backlog remaining over $400 million [7] - AST segment experienced constant currency organic revenue growth of 8%, with services growing by 9% and capital equipment revenue increasing by 103% [8] - Life sciences segment had a 5% increase in constant currency organic revenue, driven by 11% growth in consumables [9] Market Data and Key Metrics Changes - Orders in the Healthcare segment were down 1% year-to-date against tough comparisons from the previous year [7] - EBIT margins for Healthcare decreased by 100 basis points to 24.3% due to increased tariffs and inflation [7] - AST EBIT margins improved by 30 basis points to 45.1%, benefiting from pricing and volume increases [9] Company Strategy and Development Direction - The company is maintaining its fiscal 2026 outlook, expecting 8%-9% as-reported revenue growth and constant currency organic revenue growth of 7%-8% [10] - The company is focused on mitigating tariff impacts through various strategies, including supplier negotiations and cost reductions [24] - There is a commitment to a more integrated model and aggressive competition in the EMEA region [34] Management's Comments on Operating Environment and Future Outlook - Management expressed caution regarding potential slowdowns in the fourth quarter, particularly in the AST segment due to tough comparisons [13] - The macroeconomic environment appears positive, with no significant downside anticipated for fiscal 2027 [50] - Management noted that the company is well-positioned to handle tariff-related challenges and is optimistic about future performance [24] Other Important Information - The adjusted effective tax rate for the quarter was 24.2%, a slight decline from the previous year [5] - Capital expenditures for the first nine months totaled $278.8 million, with depreciation and amortization at $363.1 million [5] Q&A Session Summary Question: Thoughts on fourth quarter constant currency growth - Management cautioned about a potential slowdown in the second half and maintained the 7%-8% growth outlook due to tough comparisons from the previous year [13][14] Question: Capital equipment backlog activity - Management noted stability in Healthcare backlog and strong growth in Life Sciences backlog, attributing it to recovery from previous spending cuts [17] Question: Update on tariff mitigation efforts - Management discussed various mitigation strategies and expressed optimism about absorbing tariff costs moving forward [24] Question: Impact of regulatory proposals on supply chain - Management indicated that the ASC shift is generally positive, creating new capacity demands, but has not seen material commitments for manufacturing shifts to the U.S. yet [31] Question: Incremental tariff exposure in 2027 - Management suggested that any incremental tariff impact in 2027 would likely be less than a quarter's worth based on current tariffs [38] Question: Acquisition strategy and pipeline - Management confirmed ongoing interest in smaller acquisitions but emphasized a disciplined approach to larger transformative deals [43] Question: Cash flow guidance and fluctuations - Management expressed confidence in cash flow guidance but noted that timing and seasonal factors could affect predictions [48] Question: AST Services growth and quarter performance - Management acknowledged a weak start to the quarter but noted improvement in subsequent months, attributing some fluctuations to customer inventory adjustments [57]